IP Library Granted Patent US 7,704,738
Granted Patent B2
US 7,704,738 · App. 10/584,338 · Granted Apr 27, 2010

Definitive endoderm

Assignee: Cythera, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,704,738
App. No.
10/584,338
Granted
Apr 27, 2010
Kind
B2
Abstract

Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.

Claims (14)

1. An in vitro method of producing human definitive endoderm cells, said method comprising:

obtaining a cell population comprising pluripotent human stem cells; and

providing said cell population with a TGFβ superfamily growth factor and a Wnt family member, thereby generating in said cell population definitive endoderm cells expressing at least SOX17 and HNF3β.

2. The method of claim 1 further comprising removing TGFβ superfamily growth factor from said cell population.

3. The method of claim 1 , wherein at least 50% of said pluripotent cells differentiate into definitive endoderm cells.

4. The method of claim 1 , wherein said TGFβ superfamily growth factor is selected from the group consisting of Nodal, activin A and activin B.

5. The method of claim 1 , wherein said TGFβ superfamily growth factor is activin A.

6. The method of claim 1 , wherein said Wnt family member is Wnt3a.

7. The method of claim 1 wherein at least 10 ng/ml activin A is provided.

8. The method of claim 1 , wherein at least 100 ng/ml activin A is provided.

9. The method of claim 1 further comprising the step of providing serum to said cell population.

10. The method of claim 1 , wherein said pluripotent stem cells comprise embryonic stem cells.

11. The method of claim 10 , wherein said embryonic stem cells are derived from tissue selected from the group consisting of the morula and the inner cell mass (ICM) of the embryo.

12. The method of claim 9 , wherein providing serum comprises providing increasing concentrations of serum.

Assignments (2)
MERGER Recorded May 9, 2011
From: CYTHERA, INC.
To: VIACYTE, INC.
Reel/Frame 026256/0627 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2007
From: D'AMOUR, KEVIN ALLEN; AGULNICK, ALAN D.; BAETGE, EMMANUEL E.
To: CYTHERA, INC.
Reel/Frame 018741/0507 →
Continuity (4)
Provisional Application 6053200400 · Dec 23, 2003
Provisional Application 6058656600 · Jul 9, 2004
Provisional Application 6058794200 · Jul 14, 2004
Related Publication 20070154984A1 · Jul 5, 2007